J. Ros , V. Navarro , G. Villacampa , I. Baraibar , F. Salvà , M. Rodriguez , C. Vaghi , A. Garcia , A. Alcaraz , J. Tabernero , E. Élez , R. Dienstmann
{"title":"预测BRAF v600e突变型结直肠癌患者联合BRAF抑制剂治疗的总生存期","authors":"J. Ros , V. Navarro , G. Villacampa , I. Baraibar , F. Salvà , M. Rodriguez , C. Vaghi , A. Garcia , A. Alcaraz , J. Tabernero , E. Élez , R. Dienstmann","doi":"10.1016/j.esmogo.2025.100225","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The <em>BRAF</em> V600E mutation, found in up to 12% of patients with metastatic colorectal cancer, is associated with aggressive disease and poor response to standard chemotherapy. However, the advent of BRAF inhibitors has led to improved clinical outcomes and survival. While surrogate endpoints for predicting overall survival (OS) have been extensively studied in the overall colorectal cancer population treated with chemotherapy, their applicability in patients with <em>BRAF</em> V600E-mutant colorectal cancer receiving either BRAF inhibitor combinations or conventional chemotherapy remains unclear, and needs to be better elucidated. The aim of the study was to evaluate surrogate endpoints to predict OS in patients with <em>BRAF</em> V600E-mutant colorectal cancer treated with either BRAF inhibitor combinations or chemotherapy.</div></div><div><h3>Materials and methods</h3><div>A systematic review was carried out to identify clinical trials or real-world cohorts evaluating patients with <em>BRAF</em>-mutant colorectal cancer treated either with chemotherapy or BRAF inhibitor combinations. A control cohort of melanoma patients treated with BRAF inhibitors in a phase III randomized trial was included. Adjusted <em>R</em><sup>2</sup> (<em>R</em><sup>2</sup><sub>adj</sub>) values were calculated to quantify the association between surrogate endpoints and median OS.</div></div><div><h3>Results</h3><div>Overall, a total of 5227 patients included in 29 cohorts were analyzed. Among patients with colorectal cancer treated with chemotherapy, overall response rate (ORR) and disease control rate (DCR) showed a high correlation with OS (<em>R</em><sup>2</sup><sub>adj</sub> > 0.90). Among patients treated with targeted therapy, progression-free survival (PFS) showed the highest correlation with OS (<em>R</em><sup>2</sup><sub>adj</sub> = 0.90). In the melanoma cohort, PFS was strongly associated with OS (<em>R</em><sup>2</sup><sub>adj</sub> = 0.92).</div></div><div><h3>Conclusions</h3><div>In <em>BRAF</em>-mutant colorectal cancer, standard surrogate endpoints for chemotherapy-based treatments accurately predict OS; however, when patients are treated with targeted therapies, both ORR and PFS have proven to be reliable predictors of survival.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100225"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations\",\"authors\":\"J. Ros , V. Navarro , G. Villacampa , I. Baraibar , F. Salvà , M. Rodriguez , C. Vaghi , A. Garcia , A. Alcaraz , J. Tabernero , E. Élez , R. Dienstmann\",\"doi\":\"10.1016/j.esmogo.2025.100225\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>The <em>BRAF</em> V600E mutation, found in up to 12% of patients with metastatic colorectal cancer, is associated with aggressive disease and poor response to standard chemotherapy. However, the advent of BRAF inhibitors has led to improved clinical outcomes and survival. While surrogate endpoints for predicting overall survival (OS) have been extensively studied in the overall colorectal cancer population treated with chemotherapy, their applicability in patients with <em>BRAF</em> V600E-mutant colorectal cancer receiving either BRAF inhibitor combinations or conventional chemotherapy remains unclear, and needs to be better elucidated. The aim of the study was to evaluate surrogate endpoints to predict OS in patients with <em>BRAF</em> V600E-mutant colorectal cancer treated with either BRAF inhibitor combinations or chemotherapy.</div></div><div><h3>Materials and methods</h3><div>A systematic review was carried out to identify clinical trials or real-world cohorts evaluating patients with <em>BRAF</em>-mutant colorectal cancer treated either with chemotherapy or BRAF inhibitor combinations. A control cohort of melanoma patients treated with BRAF inhibitors in a phase III randomized trial was included. Adjusted <em>R</em><sup>2</sup> (<em>R</em><sup>2</sup><sub>adj</sub>) values were calculated to quantify the association between surrogate endpoints and median OS.</div></div><div><h3>Results</h3><div>Overall, a total of 5227 patients included in 29 cohorts were analyzed. Among patients with colorectal cancer treated with chemotherapy, overall response rate (ORR) and disease control rate (DCR) showed a high correlation with OS (<em>R</em><sup>2</sup><sub>adj</sub> > 0.90). Among patients treated with targeted therapy, progression-free survival (PFS) showed the highest correlation with OS (<em>R</em><sup>2</sup><sub>adj</sub> = 0.90). In the melanoma cohort, PFS was strongly associated with OS (<em>R</em><sup>2</sup><sub>adj</sub> = 0.92).</div></div><div><h3>Conclusions</h3><div>In <em>BRAF</em>-mutant colorectal cancer, standard surrogate endpoints for chemotherapy-based treatments accurately predict OS; however, when patients are treated with targeted therapies, both ORR and PFS have proven to be reliable predictors of survival.</div></div>\",\"PeriodicalId\":100490,\"journal\":{\"name\":\"ESMO Gastrointestinal Oncology\",\"volume\":\"9 \",\"pages\":\"Article 100225\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-08-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ESMO Gastrointestinal Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949819825000949\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Gastrointestinal Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949819825000949","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations
Background
The BRAF V600E mutation, found in up to 12% of patients with metastatic colorectal cancer, is associated with aggressive disease and poor response to standard chemotherapy. However, the advent of BRAF inhibitors has led to improved clinical outcomes and survival. While surrogate endpoints for predicting overall survival (OS) have been extensively studied in the overall colorectal cancer population treated with chemotherapy, their applicability in patients with BRAF V600E-mutant colorectal cancer receiving either BRAF inhibitor combinations or conventional chemotherapy remains unclear, and needs to be better elucidated. The aim of the study was to evaluate surrogate endpoints to predict OS in patients with BRAF V600E-mutant colorectal cancer treated with either BRAF inhibitor combinations or chemotherapy.
Materials and methods
A systematic review was carried out to identify clinical trials or real-world cohorts evaluating patients with BRAF-mutant colorectal cancer treated either with chemotherapy or BRAF inhibitor combinations. A control cohort of melanoma patients treated with BRAF inhibitors in a phase III randomized trial was included. Adjusted R2 (R2adj) values were calculated to quantify the association between surrogate endpoints and median OS.
Results
Overall, a total of 5227 patients included in 29 cohorts were analyzed. Among patients with colorectal cancer treated with chemotherapy, overall response rate (ORR) and disease control rate (DCR) showed a high correlation with OS (R2adj > 0.90). Among patients treated with targeted therapy, progression-free survival (PFS) showed the highest correlation with OS (R2adj = 0.90). In the melanoma cohort, PFS was strongly associated with OS (R2adj = 0.92).
Conclusions
In BRAF-mutant colorectal cancer, standard surrogate endpoints for chemotherapy-based treatments accurately predict OS; however, when patients are treated with targeted therapies, both ORR and PFS have proven to be reliable predictors of survival.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
